Mobile Menu - OpenMobile Menu - Closed

U.S. Representative Eddie Bernice Johnson, Representing the 30th District of Texas

Congresswoman Johnson Votes to Bring Down Prescription Drug Prices with House Passage of H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act

Dec 12, 2019
Press Release
In the 30th Congressional District of Texas, there are 75,252 people enrolled in a Medicare Part D plan and 395,773 people enrolled in private health insurance – all of whom stand to benefit from the passage of H.R.3 The Lower Drug Costs Now Act.

 

       Washington, DC – Today, Rep. Johnson voted to pass H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act, which

       will help bring down the cost of prescription drugs and level the playing field for American patients who are paying

       more for their medicines than patients in other countries. This bill also gives Medicare the power to negotiate directly  

       with drug companies. The lower prices that are negotiated by Medicare will be transparent, so that private insurance

       companies can make the same prices available to their consumers. It also creates a new $2000 out-of-pocket limit on

       prescription drug costs for Medicare beneficiaries.

 

      “Constituents in the 30th District are facing skyrocketing prescription drug prices, forcing many to choose between their

       medications and putting food on the table or meeting other basic needs,” said Congresswoman Johnson.

      “That’s unacceptable, and it’s why I pledged to make this issue one of my top priorities this year. I was proud to

      vote for H.R.3 today to deliver on that promise. I’m pleased that the bill invests the money it saves into expanding

      Medicare’s benefits to include dental, vision, and hearing; assisting innovation in the search for new cures and   

      treatments; and helping combat the opioid crisis. I urge the Senate to take up and pass H.R.3, and send it to the

      President’s desk for his signature.”  

 

  • Over the past decade the price of insulin has increased 197 percent, and Medicare Part D spending on insulin has increased 840 percent. There are 30.3 million Americans living with diabetes, including 2,333,065 people in Texas. Under H.R.3 some commonly used insulins can cost as little as $400 per year.
  • In 2019, an estimated 18,750 women in Texas will be diagnosed with breast cancer. H.R.3 can lower the average total cost of the breast cancer medication Ibrance by 65%.
  • In 2019, an estimated 4,820 people in Texas will be diagnosed with leukemia. H.R.3 can lower the average total cost of the leukemia medication Tasigna by 71%.

-continued-

 

  • In 2019, an estimated 10,660 people in Texas will be diagnosed with prostate cancer. H.R.3 can lower the average total cost of the prostate cancer medication Zytiga by 66%.
  • The 2018 Arthritis Foundation tabulations revealed that 19.8% of Texas residents have arthritis, and H.R.3 can lower their total costs on most arthritis drugs from about $40,000 to $10,000 per year.
  • The 2018 Centers for Disease Control and Prevention tabulations showed about 7.3% or 1,543,064 Texas residents live with asthma. H.R.3  can lower their total costs on most asthma drugs from about $1,400 to $270 per year.
  • In 2015, 4,358 Texas residents were diagnosed with HIV, and H.R.3 can lower their total costs on most HIV drugs from about $15,000 to $6,000 per year.

 

                                                                                      ###